Brought to you by 
Series B brings in $15mm for SpringLeaf Therapeutics
06 Jun 2011
Executive Summary
SpringLeaf Therapeutics Inc. (formerly Entra Pharmaceuticals; drug-device combination therapies) has raised $15mm through the sale of Series B preferred shares. There were six investors, including new backer GlaxoSmithKline PLC’s SR One--which led and contributes one board member--and returning shareholders Flybridge Capital Partners and North Bridge Partners. The company is developing therapeutics by bringing together new or existing therapies with a self-contained subcutaneous delivery system. SpringLeaf Therapeutics has privately raised about $27mm since it was founded in 2007, including a Series A round in 2008.
Deal Industry
- Biotechnology
- Medical Devices
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Series B brings in $15mm for SpringLeaf Therapeutics
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice